You just read:

DARZALEX® (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy

News provided by

Janssen Biotech, Inc.

Nov 21, 2016, 16:37 ET